



Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

September 27, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 27, 2023-- [Veracyte, Inc.](https://www.businesswire.com/news/home/20230927846710/en/) (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20230927846710/en/>



Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Photo: Business Wire)

"Phil is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support," said Mr. Stapley. "His experience and

expertise will be critical to further enhancing our ability to serve our customers and, ultimately, to transforming cancer care for patients all over the world."

Dr. Febbo has more than 25 years of experience across academia and industry. He most recently served as chief medical officer for Illumina where he built the medical team and led the successful strategy to engage clinical customers. Prior to that, he was chief medical officer for Genomic Health, where he oversaw the development and expansion of the company's test portfolio, including the evidence demonstrating clinical validity and clinical utility in order to drive reimbursement. Before Genomic Health, Dr. Febbo was a professor of medicine and urology at the University of California, San Francisco Medical Center, and prior to that he was an associate professor of medicine and molecular genetics and microbiology at Duke University School of Medicine. He currently serves on the board of the Reagan Udall Foundation for the U.S. Food and Drug Administration (FDA). Dr. Febbo holds a B.A. in Biology from Dartmouth College and earned his M.D. from the University of California, San Francisco. He completed his internal medicine residency at Brigham and Women's Hospital and his medical oncology fellowship at the Dana Farber Cancer Institute.

"Cancer mortality rates have started to improve due to better detection and management. Veracyte has distinguished itself with its high-performing tests that are helping physicians use underlying biology of an individual's cancer to make personalized management decisions that improve patient outcomes and healthcare efficiencies," said Dr. Febbo. "I am thrilled to join the company's talented team and to help advance the future of insight-driven care."

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: "appears," "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," "positioned," "designed" and similar references to future periods. Examples of forward-looking statements include, among others, that Dr. Febbo will help advance novel tests that address important unmet patient-care needs in cancer. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed on March 1, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2023. Copies of these documents, when available, may be found in the Investors section of our website at <https://investor.veracyte.com>. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230927846710/en/): <https://www.businesswire.com/news/home/20230927846710/en/>

Investors:

investors@veracyte.com
619-393-1545

Media:

Tracy Morris
VP of Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413

Source: Veracyte, Inc.